Luz Santibanez
Payments from drug & device makers
Across 143 payments — averaging $29.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Biohaven Pharmaceuticals, Inc.$886
- Bayer$441
- Lilly USA, LLC$439
- Nalu Medical, Inc.$247
- Dexcom, Inc.$192
- plus $895 from 14 others
What the payments were for
- Consulting fees$80019%
- Food & beverage$3,39381%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 57 | $1,093 |
| Biohaven Pharmaceuticals, Inc. | 5 | $886 |
| Bayer | 16 | $441 |
| Lilly USA, LLC | 17 | $439 |
| Nalu Medical, Inc. | 10 | $247 |
| Dexcom, Inc. | 5 | $192 |
| Tactile Systems Technology Inc | 2 | $164 |
| Boehringer Ingelheim | 5 | $137 |
| Merck | 6 | $110 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $82 |
| GSK | 4 | $75 |
| Amgen | 2 | $58 |
| Phadia US Inc. | 3 | $57 |
| Pfizer | 2 | $55 |
| Saluda Medical Americas, Inc. | 1 | $46 |
| Globus Medical | 1 | $27 |
| Exact Sciences | 1 | $24 |
| Johnson & Johnson | 1 | $23 |
| AbbVie | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$800
- Kerendia$144
- Flexitouch Plus$140
- Nimbl$140
- Nalu Neurostimulation System$135
- Ozempic$118
- DEXCOM G6 TRANSMITTER$110
- Saxenda$104
- Wegovy$104
- RYBELSUS$100
How this compares
$4,193 in reported general payments places this provider in the 85th percentile of 2,087 medical providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 37 | $39,688 |
| JanuviaSitagliptin Phosphate | 13 | $15,300 |
| OzempicSemaglutide | 18 | $15,206 |
| EliquisApixaban | 12 | $13,120 |
| Atorvastatin Calcium | 126 | $1,601 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $1,220 |
| Metformin Hcl | 70 | $770 |
| Gabapentin | 44 | $745 |
| Amlodipine Besylate | 72 | $730 |
| Losartan Potassium | 62 | $653 |
| Tamsulosin Hcl | 37 | $605 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 22 | $497 |
| Lisinopril | 52 | $478 |
| Levothyroxine Sodium | 26 | $372 |
| Alendronate Sodium | 26 | $294 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $137 | $39,68837 claims |
| MerckJanuvia | $110 | $15,30013 claims |
| Novo NordiskOzempic | $1,093 | $15,20618 claims |
| PfizerEliquis | $55 | $13,12012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,087 medical providers in California.
Other medical in Bell
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- David DoriguzziLancaster$514K
- Alison GracomIrvine$467K
- Jeffrey BonnaudLos Angeles$314K
- Ana TorresLaguna Beach$229K
- Heather ParlettRedlands$168K
- Deirdre MoxleyFullerton$149K
- Tri leGardena$127K
- Linda RankLadera Ranch$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.